Antiviral chemotherapy

Current Opinion in Pediatrics

Volumn 9, Issue 2, 1997, Pages 178-183

  Mueller, Brigitta U ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

BONE MARROW TOXICITY; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERACTIVITY; HYPERBILIRUBINEMIA; LYMPHOCYTE COUNT; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SHORT SURVEY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; VOMITING;

ADULT; ANTIVIRAL AGENTS; CHILD; HIV INFECTIONS; HUMANS; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEASE INHIBITORS; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; STAVUDINE;

EID: 0030928281     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199704000-00012     Document Type: Short Survey

References (52)

1. Dudley MN: Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995, 171(suppl 2):S99-S112.
2. Browne MJ, Mayer KH, Chafee SBD, et al.: 2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993, 167:21-29.
3. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al.: Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995, 171(suppl 2):S131-S139.
4. Griffith BP, Brett-Smith H, Kin G, et al.: Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigen. J Infect Dis 1996, 173:1252-1255. Small dose-finding study performed in 15 HIV-infected adults.
5. Skowron G: Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995, 171 (suppl 2):S113-S117.
6. Kline MW, Dunkle LM, Church JA, et al.: A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995, 96:247-252. Although they include only a relatively small number of patients, references 6 and 7 contain the only published results on the use of d4T in children.
7. Kline MW, Fletcher CV, Federici ME, et al.: Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996, 97:886-890. The only published pediatric data regarding the use of stavudine in combination with didanosine in children.
8. van Leeuwen R, Lange JMA, Hussey EK, et al.: The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992, 6:1471-1475.
9. Pluda JM, Cooley TP, Montaner JSG, et al.: A phase I/II study of 2′-deoxy-3′-thiacytidine in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995, 171:1438-1447.
10. Lewis L, Mueller B, Schock R, et al.: A phase I/II study to evaluate the safety, toxicity and preliminary efficacy of combination of lamivudine (3TC), zidovudine (AZT) and didanosine (ddl) in children with HIV infection. The Second National Conference on Human Retroviruses and Related Infections. Washington, DC: American Society of Microbiology; 1995.
11. + cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669. Double-blind study of 366 adult patients with minimal zidovudine experience comparing two different doses of lamivudine/zidovudine with a zidovudine monotherapy arm.
12. Ingrand D, Weber J, Boucher CAB, et al.: Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. AIDS 1995, 9:1323-1329.
13. Bartlett JA, Benoit SL, Johnson VA, et al.: Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996, 125:161-172. Trial in zidovudine-experienced patients comparing different combination regimens, some containing lamivudine.
14. Lewis LL, Venzon D, Church J, et al.: Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1996, 174:16-25. This is the pediatric trial that supported the simultaneous FDA approval of the drug for children and adults.
15. Merrill DP, Moonis M, Chou T-C, Hirsch MS: Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996, 173:355-364.
16. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995, 333:1657-1661.
17. Balis FM, Pizzo PA, Murphy RF, et al.: The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989, 110:279-285.
18. Balis FM, Pizzo PA, Butler KM, et al.: Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992, 165:99-104.
19. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699. Interesting theory to explain the sustained antiretroviral benefit of zidovudine/lamivudine combination therapy. Zidovudine-resistant mutants become sensitive again during combination therapy.
20. Kuritzkes DR, Quinn JB, Benoit SL, et al.: Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996, 10:975-981.
21. Wainberg MA, Drosopoulos WC, Salomon H, et al.: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996, 271:1282-1285.
22. Cheeseman SH, Hattox SE, McLaughlin MM, et al.: Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993, 37:178-182.
23. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
24. Havlir D, Cheeseman SH, McLaughlin M, et al.: High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995, 171:537-545. Small dose-finding study of 21 adult patients treated with nevirapine monotherapy.
25. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996, 124:1019-1030. Randomized, double-blind study of 398 previously treated adults with HIV infection receiving zidovudine and didanosine with or without nevirapine.
26. Carr A, Vella S, de Jong MD, et al.: A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS 1996, 10:635-641.
27. Mueller BU, Sei S, Anderson B, et al.: Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. J Pediatr 1996, 129:410-418. A small number of children had nevirapine added to zidovudine and didanosine therapy. No marked clinical benefit was seen, but interesting comparisons of viral load in blood and lymph nodes were noted.
28. Brady MT, McGrath N, Brouwers P, et al.: Randomized study of the tolerance and efficacy of high versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trial Group 128). J Infect Dis 1996, 173:1097-1106. Although zidovudine monotherapy is no longer considered standard therapy, this trial answers an important question about the dose of zidovudine for children.
29. Saravolatz LD, Winslow DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 355:1099-1106. In adult patients with advanced disease, combination therapy with zidovudine and either zalcitabine or didanosine was not found to be superior to zidovudine alone. However, this is an isolated report and it is not clear why there is such a discrepancy with other trials.
30. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 355:1081-1090. Zidovudine monotherapy resulted in more rapid disease progression than either treatment with didanosine alone or with the combination of zidovudine and didanosine, or zidovudine and zalcitabine.
31. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 355:1091-1098. Same study as in Hammer et al. (N Engl J Med 1996, 355:1081-1090) but evaluated in regard to plasma HIV RNA level and viral phenotype.
32. Englund JA, Baker CJ, McKinney RE Jr, et al.: ACTG 152: a randomized comparative trial of zidovudine (ZDV) vs didanosine (DDI) vs combination ZDV+DDI in symptomatic HIV-infected children. Third Conference on Retroviral and Opportunistic Infections. Washington, DC: American Society of Microbiology; 1996:173.
33. Johnson VA, Merrill DP, Chou TC, Hirsch MS: Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro-31-8959 and zidovudine, 2′,3′-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis 1992, 166:1143-1146.
34. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571. Resistance to protease inhibitors: an old story with new aspects.
35. Kitchen VS, Skinner C, Ariyoshi K, et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995, 345:952-955.
36. Noble S, Faulds D: Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112. Comprehensive review of saquinavir.
37. + T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
38. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017. The first trial to study the combination of a protease inhibitor with dideoxynucleosides.
39. Mueller BU, Smith S, Sleasman J, et al.: A phase I/II study of the protease inhibitor indinavir (MK-0639) in children with HIV infection. Eleventh International Conference on AIDS. Vancouver, Canada: 1996.
40. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL: A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996, 10:485-492. The only published data (except for conference proceedings) on the pharmacokinetics and safety of indinavir (based on only five patients).
41. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122. Together with the study by Ho et al. (Nature 1995, 373:123-126), this study has led to a new understanding of (as well as controversies about) viral dynamics.
42. + cells.
43. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539. Randomized, placebo-controlled, double-blind trial (duration of 12 weeks) in 52 adults.
44. Mueller BU, Zuckerman J, Nelson J, et al.: A phase I/II study of the protease inhibitor ritonavir (ABT-538) in children with HIV infection. Eleventh International Conference on AIDS. Vancouver, Canada: 1996.
45. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
46. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272:872-877.
47. Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
48. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126. Landmark paper, establishing a mathematical model for the calculation of viral dynamics.
49. Saag MS, Holodniy M, Kuritzkes DR, et al.: HIV viral load markers in clinical practice. Nature Med 1996, 2:625-629. This study takes advantage of new insights into viral and CD4 dynamics and presents preliminary guidelines for the integration of these parameters into clinical decision making.
50. Havlir DV, Richman DD: Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996, 124:984-994. Discussion of the implications of the new pathogenetic insights into viral dynamics for clinical practice.
51. Mellors JW, Rinaldo JCR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170. Baseline viral load (plasma viremia) is found to have strong predictive value for progression to death or AIDS, independent of CD4 counts.
52. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: clearance rate, infected cell lifespan, and viral generation time. Science 1996, 271:1582-1586.